Latest news with #Inclisiran
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Mankind Pharma Q4: Profit drops 10%, revenue up 27% on domestic growth
Delhi-based Mankind Pharma on Wednesday reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25) at ₹424.65 crore from ₹476.59 crore in the same period last financial year. Mankind's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. Commenting on the results, Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. According to the company, its share in the domestic market increased from 4.4 per cent in March 2024 to 4.8 per cent as of March 2025. It was on account of BSV acquisition and leadership in the gynaecology segment. Mankind had completed the acquisition of 100 per cent stake in BSV for ₹13,768 crore in October 2024. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. Mankind's consumer healthcare segment also reported a revenue growth of 14 per cent in Q4. The export business witnessed a growth of 100 per cent in the March quarter. It was driven by an increase in the base business and launches in the past one-two years, among others. The company declared its results after market hours. On Wednesday, Mankind Pharma's share went down marginally by 0.69 per cent, ending the day's trade at ₹2,533.03 on the BSE.
Yahoo
27-03-2025
- Business
- Yahoo
Novotech Report Reveals Growth in siRNA Research: Over 150 Industry-Sponsored Clinical Trials Conducted from 2020 to 2024
SYDNEY, March 27, 2025--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of small interfering RNA (siRNA) therapeutics. This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to develop next-generation treatments for oncology, metabolic disorders, and rare genetic diseases. Unlocking the Potential of siRNA for Drug Development siRNA therapeutics represent a paradigm shift in targeted drug development by enabling precise gene silencing of disease-causing genes. With the FDA approval of multiple siRNA-based drugs, including ONPATTRO™ (Patisiran) and Inclisiran, the field is witnessing rapid advancements in delivery platforms, stability, and tissue-specific targeting. Novotech's report outlines the current research and regulatory landscape, highlighting how siRNA technologies are expanding the druggable genome, addressing previously undruggable targets. Key highlights Clinical and Regulatory Landscape: Overview of the six FDA-approved siRNA therapies and their expanding indications in cardiovascular, hepatic, and rare genetic diseases. Advancements in siRNA Delivery: Innovations in lipid nanoparticles (LNPs), GalNAc conjugates, and polymeric nanoparticles enhancing targeted tissue delivery and minimizing immune-related challenges Expanding Applications in Oncology: siRNA's role in silencing oncogenes, overcoming drug resistance, and targeting tumor microenvironments, positioning it as a promising alternative to traditional cancer treatments. Clinical Trial Growth & Future Outlook: Analysis of the 150+ industry-sponsored siRNA clinical trials conducted between 2020 and 2024, with a 79.5% CAGR reflecting significant industry investment. Partnering for Success in siRNA Clinical Development As a leading global provider of end-to-end clinical trial services, Novotech partners with biotech and pharmaceutical innovators to accelerate the development of siRNA therapeutics. With expertise in RNA research and over 25 years of experience in clinical trial execution, Novotech provides the comprehensive regulatory guidance, strategic site selection, and expert trial management to navigate the complexities of siRNA drug development-ensuring efficiency, compliance and success at every phase. Download the Full Report About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations. Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years. For more information or to speak to an expert team member visit View source version on Contacts Media Contact Toyna Chin mediacontact@ USA: +1 415 364 8135 Sign in to access your portfolio
